Pluri Inc. income statement PLUR

Annual Quarterly

In fiscal 2026, which ended Jun 30, 2026, Pluri Inc. reported revenue of $1.0 million, down 24.0% from the year before. It recorded a net loss of $23.8 million. The operating loss came to $24.9 million, an operating margin of -2454.5%. Diluted earnings per share were -$2.44. Across the 8 fiscal years shown, revenue grew from $50,000 in fiscal 2018 to $1.0 million in fiscal 2026, about 53.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Jun 30, 2025	FY 2024 Jun 30, 2024	FY 2023 Jun 30, 2023	FY 2022 Jun 30, 2022	FY 2021 Jun 30, 2021	FY 2020 Jun 30, 2020	FY 2019 Jun 30, 2019	FY 2018 Jun 30, 2018	FY 2017 Jun 30, 2017
Revenue	1 -24.0%	1 +309.8%	0 +13.6%	0 +22.6%	0 +917.4%	—	0 -57.4%	0 +8.0%	0 -98.2%	—
Cost of revenue	1 -17.4%	1 +16950.0%	0 -55.6%	0	—	—	—	0 +0.0%	0 -98.0%	—
Gross profit	0 -30.7%	1 +103.1%	0 +15.8%	0	—	—	0 -55.8%	0 +8.3%	0 -98.3%	—
Research and development	15 +17.4%	13 +3.3%	12 -21.0%	16 -36.0%	25 -19.4%	31 +32.2%	23 -22.7%	30 +13.3%	26 +9.9%	24 +5.0%
Selling, general and administrative	10 +3.2%	10 -0.5%	10 -14.8%	12 -32.5%	17 -15.1%	21 +159.5%	8 -13.5%	9 -18.2%	11 +61.6%	7 +6.8%
Other operating income (expense)	0	—	2	—	—	—	—	—	0	—
Operating income	-25 -12.5%	-22 -0.1%	-22 +18.7%	-27 +34.5%	-42 +17.8%	-51 -71.7%	-29 +17.0%	-36 -5.3%	-34 -20.4%	-28 -20.2%
Interest income	0 -57.3%	1	—	—	—	—	—	—	—	—
Interest expense	1 +6.8%	1 +0.8%	1	—	—	—	—	—	—	—
Other non-operating income (expense)	0 +331.1%	-0 -112.3%	2	—	—	—	—	-0 +92.0%	-0	—
Other income (expense)	-0 +57.7%	-1 -232.6%	1 +149.6%	-2 -849.3%	0	—	0 +44.0%	0 -97.0%	8 +3609.8%	0 +180.8%
Pretax income	-25 -9.2%	-23	—	—	—	—	—	—	—	—
Income tax	-0 -400.0%	-0	—	—	—	—	—	—	—	—
Net income	-24 -5.5%	-23 -8.1%	-21 +26.2%	-28 +31.3%	-41 +17.3%	-50 -71.1%	-29 +17.4%	-35 -35.1%	-26 +6.1%	-28 -19.7%
Net income to common	9,417 +48.7%	6,332	—	29 -30.2%	41 -17.0%	50	—	—	—	—
Basic EPS	-2.44 +31.5%	-3.56 +10.8%	-3.99 +36.1%	-6.24 -387.5%	-1.28	—	—	—	—	—
Diluted EPS	-2.44 +31.5%	-3.56 +10.8%	-3.99 +36.1%	-6.24 -387.5%	-1.28	—	—	—	—	—
Weighted average shares, basic	10 +53.8%	6 +20.9%	5 +14.4%	5 -85.8%	32	—	—	—	—	—
Weighted average shares, diluted	10 +53.8%	6 +20.9%	5 +14.4%	5	—	—	—	—	—	—
Other measures
Depreciation and amortization	1 +61.7%	0 +24.9%	0 -30.1%	0 -65.6%	1 -23.1%	1 -12.7%	2 -20.0%	2 -2.8%	2 -7.3%	2 +1.3%
EBITDA	-24 -11.7%	-22 +0.2%	-22 +18.5%	-27 +33.7%	-41 +17.7%	-49 -76.5%	-28 +16.9%	-34 -5.9%	-32 -22.7%	-26 -22.1%
Interest coverage	-26.76x	-25.40x	-25.59x	—	—	—	—	—	—	—
Margins
Gross margin	44.59%	48.95%	98.77%	96.86%	—	—	100.00%	96.30%	96.00%	—
Operating margin	-2,454.53%	-1,659.88%	-6,796.93%	-9,493.38%	-17,774.79%	—	-128,156.52%	-65,800.00%	-67,462.00%	—
Pretax margin	-2,499.41%	-1,740.64%	—	—	—	—	—	—	—	—
Profit margin	-2,344.59%	-1,690.34%	-6,407.36%	-9,867.94%	-17,624.79%	—	-126,747.83%	-65,383.33%	-52,252.00%	—
EBITDA margin	-2,404.23%	-1,636.23%	-6,719.33%	-9,367.25%	-17,324.79%	—	-121,330.43%	-62,166.67%	-63,426.00%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: PLUR (Nasdaq)
Fiscal year ends: June 30
Incorporated in: NV
Headquarters: Haifa
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1158780
Former names: PLURISTEM THERAPEUTICS INC (until Jul 13, 2022); PLURISTEM LIFE SYSTEMS INC (until Dec 28, 2007); AI SOFTWARE INC (until Jul 1, 2003)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.